Highlights

• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 19, 2016, págs. 2041-2043
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Animal data and clinical studies demonstrate neuroprotective effects of erythropoietin (EPO). In a randomized placebo-controlled trial that enrolled 448 very preterm infants, Natalucci and colleagues assessed the effect of prophylactic early high-dose recombinant human EPO (rhEPO) on neurodevelopmental outcomes at age 2 years. Neurodevelopmental outcome data were available for 365 infants. The authors found no significant differences in neurodevelopmental outcomes among infants who received rhEPO compared with those who received placebo.